In animals treated with a single dose of PrP-lowering antisense oligonucleotide, astrogliosis remained low even as the drug washed out and animals eventually developed terminal prion disease (3), and GFAP staining was reduced in treated animals that reached the endpoint (2). This evidence concerns the gene GFAP and prion disease.